Phio Pharmaceuticals is a biotechnology company whose INTASYL self-delivering RNA interference technology platform improves the immune cells in killing tumor cells. Co.'s pipeline includes: PH-762, which is designed to reduce the expression of cell death protein 1; PH-894, which is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells; PH-804, which is designed to target TIGIT, a protein that inhibits the activity of Natural Killer cells; PH-109, which is designed to suppress the connective tissue growth factor protein; and an INTASYL compound that is designed to target CTLA-4, a protein that inhibits the ability of T cells to kill tumor cells. The PHIO YTD return is shown above.
The YTD Return on the PHIO YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether PHIO YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PHIO YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|